5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.94▲ | 1.96▼ | 1.96▼ | 2.00▼ | 2.16▼ |
MA10 | 1.96▼ | 1.98▼ | 1.99▼ | 2.22▼ | 2.17▼ |
MA20 | 2.01▼ | 2.04▼ | 2.08▼ | 2.21▼ | 2.10▼ |
MA50 | 2.19▼ | 2.27▼ | 2.35▼ | 2.21▼ | 2.39▼ |
MA100 | 2.32▼ | 2.31▼ | 2.26▼ | 2.10▼ | 3.47▼ |
MA200 | 2.37▼ | 2.24▼ | 2.26▼ | 2.20▼ | 10.56▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.004▲ | -0.003▼ | -0.045▼ | 0.013▲ |
RSI | 36.864▼ | 31.334▼ | 30.576▼ | 40.903▼ | 45.960▼ |
STOCH | 30.952 | 24.254 | 17.770▼ | 9.004▼ | 10.348▼ |
WILL %R | -59.259 | -73.171 | -76.596▼ | -90.648▼ | -94.320▼ |
CCI | -54.886 | -92.316 | -87.556 | -90.670 | -80.938 |
Friday, September 26, 2025 02:16 PM
SAB Biotherapeutics ( ($SABS) ) has issued an announcement. On September 26, 2025, SAB Biotherapeutics held a special meeting where stockholders ...
|
Friday, September 19, 2025 04:36 AM
As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in ...
|
Wednesday, September 03, 2025 09:05 AM
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/10/25 | 1.95 | 1.95 | 1.95 | 1.95 | 6,306 |
30/09/25 | 1.95 | 2.0248 | 1.85 | 2.01 | 106,550 |
29/09/25 | 2.04 | 2.10 | 1.89 | 1.95 | 208,078 |
26/09/25 | 2.06 | 2.16 | 1.98 | 2.01 | 199,157 |
25/09/25 | 2.15 | 2.185 | 2.03 | 2.10 | 156,804 |
24/09/25 | 2.23 | 2.35 | 2.14 | 2.16 | 221,752 |
23/09/25 | 2.47 | 2.4926 | 2.20 | 2.26 | 203,738 |
22/09/25 | 2.45 | 2.55 | 2.36 | 2.48 | 162,145 |
19/09/25 | 2.80 | 2.90 | 2.33 | 2.47 | 822,766 |
18/09/25 | 2.60 | 2.9193 | 2.54 | 2.79 | 794,619 |
|
|
||||
|
|
||||
|
|